Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.51B |
| Revenue (ttm) | 578.74M |
| Net Income (ttm) | 67.69M |
| Shares Out | 57.68M |
| EPS (ttm) | 1.16 |
| PE Ratio | 22.69 |
| Forward PE | 18.81 |
| Dividend | 0.73 (2.84%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 45,437 |
| Average Volume | 85,922 |
| Open | 2,590.00 |
| Previous Close | 2,626.00 |
| Day's Range | 2,542.00 - 2,596.00 |
| 52-Week Range | 1,956.00 - 3,045.00 |
| Beta | 0.21 |
| RSI | 62.44 |
| Earnings Date | Feb 11, 2026 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Full Company ProfileFinancial Performance
In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.
Financial numbers in USD Financial StatementsNews
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers
Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026
Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026
Kamada forecasts double-digit profitable growth in 2026
Kamada forecasts 2026 revenue of $200M–$205M and adjusted EBITDA of $50M–$53M, driven by organic growth.
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
REHOVOT, Israel, and HOBOKEN, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Kamada Ltd Corporate Update Call Transcript
Kamada Ltd Corporate Update Call Transcript
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD) . Kamada stock is feeling bearish pressure. Why are ...
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook December 8, 2025 8:30 AM ESTCompany...
Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency
Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency
Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Q3 2025 Kamada Ltd Earnings Call Transcript
Q3 2025 Kamada Ltd Earnings Call Transcript
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...
Kamada (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Q3 2025 Earnings Call Transcript
Kamada (KMDA) Misses Q3 Earnings Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Confirms 2025 Financial Outlook with Strong Growth Expectations
Kamada (KMDA) Confirms 2025 Financial Outlook with Strong Growth Expectations
Kamada GAAP EPS of $0.09 in-line, revenue of $47M misses by $0.22M; reaffirms FY outlook
Kamada reports Q3 GAAP EPS in line at $0.09; revenue grows 12.6% to $47M but misses expectations.
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ: CBAT) is likely to report quarterly loss at $0.04 per share on revenue of $39.27 million. • Townsquare Media (NYSE: TSQ) is estimated ...
An Overview of Kamada's Earnings
Kamada (NASDAQ: KMDA) will release its quarterly earnings report on Monday, 2025-11-10. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Kamada to report an earnin...
Kamada Q3 2025 Earnings Preview
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result
Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e...
Should Value Investors Buy Kamada (KMDA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...